IVA Share Price Performance
€4.10
1.95 (91.36%)
59.1% undervalued intrinsic discount
€10.00
Fair Value
Price €4.10
AnalystHighTarget €10.00
AnalystConsensusTarget €7.85
Fair Value€10.00
Share Pricen/a
Inventiva S.A. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 13 Fair Values set on narratives written by author
IVA Community Narratives
AN
Fair Value €10 59.1% undervalued intrinsic discount
Global Aging Trends Will Spark Demand For MASH Treatments
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value €7.85 47.8% undervalued intrinsic discount
Analysts Boost Inventiva Price Target Amid Optimism for MASH Market and Pipeline Progress
0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
Analysts Boost Inventiva Price Target Amid Optimism for MASH Market and Pipeline Progress
Key Takeaways Strategic focus on lanifibranor development, cutting other activities, and reducing workforce may improve net margins through operational efficiency. Key partnerships in Asia and financial strength ensure market penetration and support sustained investment, boosting future earnings potential.Read more
108
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AN
€7.85
47.8% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
117.94% p.a.
Profit Margin
41.15%
Future PE
22.33x
Price in 2029
€11.6
Global Aging Trends Will Spark Demand For MASH Treatments
Key Takeaways Leadership in multimodal metabolic therapies and innovative clinical positioning could drive outsized revenue and expand Inventiva's market reach over time. Decisive restructuring and strategic partnerships enhance margins and acquisition appeal, positioning the company for industry-leading financial performance and transformative growth opportunities.Read more
13
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
€10
59.1% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
188.17% p.a.
Profit Margin
64.78%
Future PE
7.65x
Price in 2028
€17.48
Trending Discussion
Recently Updated Narratives
AN
IVA: 2026 Phase 3 MASH Readout Expected To Unlock Upside Repricing
Fair Value: €7.85 47.8% undervalued intrinsic discount
9 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Global Aging Trends Will Spark Demand For MASH Treatments
Fair Value: €10 59.1% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Inventiva S.A. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -1.63
- 95.19%
- -1,833.03%
- -1,445.4%
About IVA
- Founded
- 2011
- Employees
- 84
- CEO
- WebsiteView website
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France.
